. 2007 May 31;4(Suppl 6):3–10. doi: 10.1111/j.1524-6175.2002.01886.x

Table V.

Results of an ARB‐Based (Losartan) Compared With a β Blocker‐based (Atenolol) Treatment Program in 1195 Diabetic Hypertensive Patients With Left Ventricular Hypertrophy*

Event	Difference ARB/β Blocker
Achieved blood pressure (mm Hg)	−2/0^†
Primary end point (CV mortality stroke, myocardial infarction)	−24
Death from CV disease	−37
Heart failure	−41
All‐cause mortality	−39
ARB=angiotensin receptor blocker; CV=cardiovascular; *No significant differences between medications in stroke and myocardial infarction; ^†ARB, 146/79 mm Hg; β blocker, 148/79 mm Hg Data derived from Lindholm et al. ²⁴